Olive Tree Ventures

Olive Tree Ventures (OTV) Research Investment Thesis Olive Tree Ventures (OTV), formerly known as Olive Tree Ventures, is a specialized venture capital fund focused exclusively on digital health innovation. The fund was founded in 2015 by experienced entrepreneurs who have collectively founded seven successful companies generating over $4 billion in shareholder value. OTV invests in mid-growth stage digital health startups that aim to make a significant impact on people's lives and advance global health outcomes. The firm's core thesis is that digital health startups need experienced champions who can guide them through scaling challenges. OTV partners with founders to identify and fund disruptive innovations in the digital health space that improve diagnosis rates, develop new treatments, and boost wellbeing worldwide. The fund believes that the digital health market, which has grown 150% since 2017, represents a massive opportunity to build companies that are both financially successful and socially impactful. Sector Focus OTV invests exclusively in the digital health sector, which encompasses a broad range of innovations: Telehealth and Remote Care: Platforms enabling on-demand medical consultations and remote patient monitoring (e.g., TytoCare, Lemonaid Health) Genomic Medicine and Diagnostics: AI-powered interpretation of genomic data and diagnostic tools (e.g., Emedgene) Digital Therapeutics and Behavioral Health: Technology solutions for chronic disease management, mental health, and lifestyle modification (e.g., Donisi) Medical Devices and Wearables: Connected health monitoring devices and precision health technologies (e.g., MedaSense, Scopio Labs) Healthcare Infrastructure: Platforms improving healthcare access, affordability, and operational efficiency (e.g., mPharma, HygieaCare) Medical Technology: Next-generation solutions in surgical innovation, visualization, and treatment delivery Smart Glass and AR/VR: Emerging technologies for medical visualization and collaboration (e.g., Gauzy) The fund explicitly avoids pure pharmaceutical development, hardware-only plays, and non-digital health investments. Stage Focus OTV primarily invests at the mid-growth stage, which corresponds to: Series A and Beyond: Companies with initial product-market validation and scaling potential Late Seed: Well-developed products with initial customer traction and clear growth trajectory Selective Pre-Seed: Exceptional technical founders with strong domain expertise and proven management track records The fund typically follows in rounds, providing significant operational support and advisory services. Check Size and Fund Information Typical Investment Range: $500,000 - $1,500,000 Fund Size: $170 million (Fund I, closed December 2020) Check Size Strategy: Concentrated portfolio approach with about a dozen portfolio companies per fund Follow-on Reserves: 50% of fund reserved for follow-on investments in existing portfolio The fund takes concentrated positions and is selective with deal flow, preferring quality over quantity. Lead Tendency OTV primarily follows in rounds, though it will occasionally lead Series A investments. The firm's strength lies in its operational expertise and advisory support to existing portfolio companies rather than aggressively leading new investments. Recent Activity and Fund Status OTV's most recent major announcement was the closure of a $170 million dedicated digital health fund in December 2020. The fund has been actively deploying capital with notable investments including TytoCare, Lemonaid Health, Emedgene, Donisi Health, Scopio Labs, MedaSense, Via Surgical, and Gauzy. Notable Portfolio Exits: Atrica (acquired by Nokia) - Mobile infrastructure platform CFR Pharmaceuticals (acquired by Abbott) - Pharmaceutical company Ice.com (acquired by Round2) - Digital jewelry commerce Dynamic Yield (acquired by McDonald's) - AI personalization platform Nutranext (acquired by Clorox) - Dietary supplements company Zimperium (acquired by Liberty Capital) - Mobile security platform WM Partners/Worthy (acquired/merged) - Luxury and wellness platforms The fund shows strong exit history with acquisitions by major corporations including Abbott, Nokia, and McDonald's, demonstrating ability to build companies to meaningful scale. Fund Status: Actively deploying capital from Fund I ($170M). Portfolio Highlights OTV's portfolio includes a diverse range of digital health companies across telehealth, diagnostics, genomics, chronic disease management, medical devices, healthcare access, and emerging medical technologies. Team OTV's leadership team combines deep healthcare expertise with successful entrepreneurial track records: Mayer Gniwisch, General Partner: Serial entrepreneur (Ice.com, Diamond.com, Mpharma, Stor.ai), Harvard Business School Amir Lahat, General Partner: Technology infrastructure expertise (Telrad/Nortel, 3Com, Atrica), Stanford and Kauffman Fellow Alejandro Weinstein, General Partner: Healthcare and pharmaceutical expertise (CFR/Abbott, genomics), Harvard Business School Henry Weinstein, Principal: Pharmaceutical operations and investment expertise (CFR/Abbott, INSEAD, Wharton) The team collectively brings $4B+ in successful exits and deep digital health market knowledge. Geographic Focus OTV invests across multiple regions including North America, Europe, Latin America, Africa, MENA, and Asia. The firm's tri-continental team and market access provide competitive advantage in identifying and supporting global digital health opportunities. Decision Process OTV operates as a partnership model where decisions are collaborative but efficient. The firm emphasizes a personable and supportive selection process focused on founder alignment and operational fit rather than purely financial metrics. Investment Selection Process OTV's selection process includes: Deal sourcing through referrals from existing portfolio and passed companies In-depth due diligence on product fit and team Personable meetings focused on understanding founder strengths Partnership approach providing capital, operational guidance, network access, and scaling expertise Competitive Advantages Experienced team with $4B+ in successful exits Operational expertise from serial entrepreneurs in healthcare Global tri-continental presence and market access Deep digital health vertical expertise Strong healthcare company exit track record Founder partnership focus over control Market Position OTV is positioned as a specialist digital health fund with strong operational expertise and global reach. The digital health market is expected to reach $540 billion by 2025, with healthcare digitization accelerating and enterprise buyers actively seeking innovation.